Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $44.4 million.

  • Bicycle Therapeutics' Accumulated Expenses rose 1285.83% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 1285.83%. This contributed to the annual value of $41.2 million for FY2024, which is 3090.23% up from last year.
  • Bicycle Therapeutics' Accumulated Expenses amounted to $44.4 million in Q3 2025, which was up 1285.83% from $44.5 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Accumulated Expenses registered a high of $44.5 million during Q2 2025, and its lowest value of $9.7 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $26.5 million (2022), whereas its average is $26.6 million.
  • In the last 5 years, Bicycle Therapeutics' Accumulated Expenses soared by 11980.89% in 2023 and then plummeted by 2449.41% in 2024.
  • Bicycle Therapeutics' Accumulated Expenses (Quarter) stood at $14.2 million in 2021, then surged by 85.71% to $26.5 million in 2022, then increased by 19.12% to $31.5 million in 2023, then soared by 30.9% to $41.2 million in 2024, then rose by 7.57% to $44.4 million in 2025.
  • Its Accumulated Expenses stands at $44.4 million for Q3 2025, versus $44.5 million for Q2 2025 and $34.0 million for Q1 2025.